Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.

Curr Oncol · 2023 · PMC10605250 · PMID 37887546

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

However, age was not independently associated with OS ( p = 0.59), and the combination of ipilimumab plus nivolumab showed a trend of independent association ( p = 0.07) in multivariate analysis.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.